Video

Strategies For Communicating Cardiovascular Risk to Patients Starting on ADT

Urologist David Morris, MD, FACS, shares his perspective on communicating cardiovascular risk to patients starting androgen deprivation therapy.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      January 2023 AbbVie Inc. Company Confidential

      Newsletter

      Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

      Subscribe Now!
      Related Videos
      Laura Davis, MD, on persistent poverty and early onset prostate cancer
      Laura Davis, MD, on persistent poverty and early onset prostate cancer
      Alicia Morgans, MD, highlights the phase 3 ARASTEP trial
      Alicia Morgans, MD, highlights the phase 3 ARASTEP trial
      Ruben Olivares, MD, answers a question during a Zoom video interview
      Ruben Olivares, MD, discusses HIFU and remote prostate cancer care
      Mitchell Huang, MD, on the cost-effectiveness of transperineal vs transrectal prostate biopsy
      Mitchell Huang, MD, on the cost-effectiveness of transperineal vs transrectal prostate biopsy
      Alicia Morgans, MD, on QOL outcomes with darolutamide plus ADT in mHSPC
      Alicia Morgans, MD, on QOL outcomes with darolutamide plus ADT in mHSPC
      Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
      Post-RP incontinence: Low procedure rates examined
      Bashir Al Hussein Al Awamlh, MD, MPH, answers a question during a Zoom video interview
      Data link incontinence severity to post-radical prostatectomy care
      Jim Hu, MD, on upgrading of GG1 prostate cancer at radical prostatectomy
      Jim Hu, MD, on upgrading of GG1 prostate cancer at radical prostatectomy
      Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
      Expert discusses differentiating prostate cancer from age-related issues
      Murilo De Almeida Luz, MD, on PSA and ALP changes with enzalutamide/radium-223
      Murilo De Almeida Luz, MD, on PSA and ALP changes with enzalutamide/radium-223
      Related Content
      Man talking with doctor | Image Credit: © Chinnapong - stock.adobe.com
      July 7th 2025

      FDA and EMA authorize phase 3 trial of masitinib for mCRPC

      Benjamin P. Saylor
      For the trial, a biomarker will be utilized to aid in patient selection for the treatment.
      Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
      April 27th 2025

      Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

      Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
      Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
      Regulatory recap: FDA approvals in urology from the first half of 2025
      July 4th 2025

      Regulatory recap: FDA approvals in urology from the first half of 2025

      Hannah Clarke
      Take a look through all the regulatory milestones in urology from the first half of the 2025.
      Dr. Murphy on increasing diversity in cancer clinical trials
      February 29th 2024

      Dr. Murphy on increasing diversity in cancer clinical trials

      Urology Times staff
      In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
      FDA logo
      July 3rd 2025

      FDA news recap in urology for Q2 2025

      Hannah Clarke Benjamin P. Saylor Jason M. Broderick
      Here’s a look back at notable news between April and June 2025.
      Enrollment begins in phase 2 trial of opaganib plus darolutamide in mCRPC
      July 2nd 2025

      Enrollment begins in phase 2 trial of opaganib plus darolutamide in mCRPC

      Hannah Clarke
      The study will utilize the companion lipid biomarker test, PCPro, to identify patients who may benefit from the addition of opaganib to darolutamide.
      © 2025 MJH Life Sciences

      All rights reserved.